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resulting in a very high anaerobic glycolytic rate. Despite the fact that 
squamous cell carcinomas have a higher 18FDG-uptake, in general 
regarded as a poor prognostic factor, adenocarcinomas had a higher 
metastatic potential and a worse DFS. Therefore, the prognostic 
potential of 18FDG-PET should be interpreted in relation to histology. 
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Purpose/Objective: Treatment policy of inoperable or irresectable 
NSCLC (inop/irresNSCLC) in our department is consistant from 1995 
and onwards and has been guided by results of several subsequent 
EORTC studies (08844,08912,08972). Cc RT to a dose of 66 Gy/24 fx 
/2,75 Gy/33 days was combined with daily administration of cisplatin 
6mg/m2 1-2 hours before RT (total planned dose 144 mg/ m²) in 
patients with inop or irres disease (ccRCT). Patients were restaged 
and a resection (S) was considered in case of downstaging and strong 
indication or evidence of residual tumor, if radical S by lobectomy 
seemed feasible. Results of ccRCT from 1995-2004 were analysed and 
reported before. The 5 yr overall survival (OS) was 15%, the 5 yr local 
control rate (LCR) was 46 %. PET-staging was gradually introduced in 
our clinic in 2004 and became a standard staging procedure end of 
2006. 
The aim of the present study is to analyse the influence of PET staging 
on treatment results, and to check if our treatment is still appropiate 
in PET staged pts with inop/irresNSCLC. 
Materials and Methods: From2005-2012 136 pts were treated with cc 
RCT or RT. Eligibility criteria: biopsy proven irres or inop NSCLC not 
eligible for stereotactic radiotherapy, clinical and radiological 
suspicion for malignancy, FeV1>1 l, DLCO≥40%, adequate renal, 
haematological and pulmonary function (FeV1≥30 %). Chemotherapy 
was given in 118 pts and consisted of cisplatin 6 mg/m² in 112 pts (in 
6 pts preceded and in one patient followed by 2 courses of standard 
dose platinum containing chemotherapy, SDPtCT). 6 pts received 2 
courses of SDPtCT before RT. Radiotherapy was given by a conformal 
technique in all pts, elective treatment was omitted. The dose was 
defined according to the ICRU50 report. Dose constraints: max dose to 
spinal cord: 50 Gy/2 Gy or equivalent dose, MLD ≤20%, V20 ≤ 40%, 
V35oes ≤65%, max heart dose 40Gy (whole heart) or 50 Gy to 2/3 of 
the heart. Surgery was performed in 11 pts. 
Results: Stage (TNM2007) I, II, III, VI:12,10,101 (74,3%), 4 pts (solitary 
brain metastasis), unknown 9 pts. PET staging: 124 pts. Histology in 
128 pts: scc: 42pts, adenoca: 17pts, large cell undifferentiated ca: 60 
pts, malignant ca nos: 9 pts. Result in pts without histological 
diagnosis was equal to result in other pts. OS: The 1,2 and 5yr 
actuarial OS was 86%, 59% and 31% respectively (resp), mean S 49 
months (m) (95 % CI 38-62 m), median 33m. The 1, 2 and 5 yr LCR was 
83%, 69% and 51%. Mean and median follow-up period was 20 and 15m 
resp., (1,7-88). Late toxicity gr 1,2, 3,4 was present in 3,1,7 and 2 pts 
resp. Two pts died of complications. 
Results of S: lobectomy 10x, bilobectomy 1x. R0:9x, R1:1x, 
irresectable 1x. 
  
Conclusions: Selection of pts with inop/irres NSCLC by staging with 
PET-CT scan before ccRCT consisting of low dose cisplatin 6 mg/ m² 
given cc with radiotherapy 66 Gy/24 fx/33 days leads to an impressive 
increase in 5 yr OS(15to 31%) with similar LC 46-51%). The results are 
comparable with results of combined modality treatment with full 
dose RCT but with less toxicity. 
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Purpose/Objective: To retrospectively assess treatment outcome, and 
toxicity after a moderately escalated hypofractionated radiotherapy 
delivered with Helical Tomotherapy (HT) in locally advanced stage III 
inoperable non-small cell lung cancer (NSCLC) combined with 
sequential or concurrent chemotherapy. 
Materials and Methods: Sixty-one eligible patients were treated with 
combined platinum-based chemotherapy associated with a moderately 
escalated hypofractionated radiation course delivered with HT. The 
treatment schedule consisted of 30 daily fractions ranging from 2.25 
to 2.28 Gy each up to a total dose of 67.5-68.4 Gy to the gross tumour 
volume considered as the primary site and clinically proven nodal 
regions, without elective nodal irradiation. Applying a/bratio of 10, 
the corresponding normalized total dose at 2 Gy per fraction (NTD2) 
was 68.9-70 Gy. Overall survival and local control were assessed as 
well as acute and late toxicity using National Cancer Institute 
Common Terminology Criteria and Adverse Events (CTCAE) version 
3.0. 
Results: No Grade≥ 4 acute and late toxicity was reported. Acute 
Grade 3 treatment-related pneumonitis was detected in 12% of 
patients. Two patients, both receiving the concurrent 
schedule,developed a Grade 3 acute esophagitis. The overall 
incidence of late Grade 3 lung toxicity was 7%. No patients 
experienced a Grade 3 late esophageal toxicity. After a median 
follow-up of 25 months (range, 6-40 months), 2-year local control and 
overall survival rates were 65% and 53% for all patients, 30% of whom 
were stage IIIB. The same features for patients who received 
concurrent chemoradiation were 72% and 56%, respectively.  
Conclusions: Our findings show that a moderately hypofractionated 
radiation course delivered with HT is a feasible treatment option for 
patients with inoperable locally advanced NSCLC receiving 
chemotherapy (sequentially or concurrently). Hypofractionated 
radiotherapy with a dedicated technique allows safely dose 
escalation, minimizing the effect of tumor repopulation that may 
occur with prolonged treatment time. 
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